Oneness has been invited for a poster presentation with on-site Q&A for the Phase 3 MRCT post-hoc analysis of the DFU new drug, Fespixon at IDF Congress 2022.

Published Date:2022-12-06

Statement
No	1	Date of announcement	2022/12/06	Time of announcement	17:07:51
Subject	Oneness has been invited for a poster presentation with on-site Q&A for the Phase 3 MRCT post-hoc analysis of the DFU new drug, Fespixon at IDF Congress 2022.
To which item it meets	paragraph 12			Date of events	2022/12/07
Date of institutional investor conference: 2022/12/07 Time of institutional investor conference: 21:20 (TPE time) Location of institutional investor conference:Lisbon, Portugal Outline of institutional investor conference: (1) Oneness has been invited for a poster presentation with on-site Q&A for the Phase 3 MRCT post-hoc analysis of the diabetic foot ulcer new drug, Fespixon at IDF Congress 2022. (2) Established in 1950, the International Diabetes Federation (IDF) is composed of more than 240 diabetes associations in 170 countries, and also the representative organization in leading the global diabetes community. The IDF Congress is held every two years to update the R&D progress in diabetes care, treatment, prevention, and related complications, and is attended by more than 12,000 physicians, scientists, nursing staffs, educators, other healthcare professionals, government representatives, policymakers, etc. Any other matters that need to be specified:The poster will be uploaded to Market Observation Post System according to the regulation.